Research & Development

Johnson & Johnson launches multi-pronged response to coronavirus global public health threat

Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak.

Accenture selects Google Cloud as cloud technology provider for INTIENT

Accenture has entered into a technology collaboration with Google Cloud with an objective to help life sciences companies advance the discovery, development, and delivery of their innovative therapies.

Alexion wraps up $930m acquisition of Achillion

Alexion Pharmaceuticals has completed the acquisition of clinical-stage biopharmaceutical company Achillion Pharmaceuticals for around $930m.

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated lab of future

HighRes Biosolutions and Novo Nordisk announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation.

US reports first case of novel coronavirus from China-returned traveller

The US Centers for Disease Control and Prevention (CDC) has reported the first case of 2019 Novel Coronavirus (2019-nCoV) in the US state of Washington following the return of a patient from China who tested positive to the virus.

Clarivate Analytics to buy Decision Resources Group for $950m

Clarivate Analytics has agreed to acquire Decision Resources Group (DRG) from Piramal Enterprises in a deal valued at around $950m.

Civica Rx partners with Thermo Fisher Scientific to develop and manufacture drugs with a history of drug shortages

Civica Rx (Civica, Inc.) today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway.

Merck wraps up $2.7bn acquisition of biopharmaceutical firm ArQule

Merck has completed the acquisition of US-based biopharmaceutical company ArQule in a deal valued at around $2.7bn.

Twist Bioscience announces strategic collaboration with Schrödinger for drug discovery

Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a collaboration with Schrödinger, a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ technology platforms together to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.